Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

8.5K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
8.5K
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

2.1K
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
2.1K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

2.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
2.2K
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

1.1K
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
1.1K
Dialysis01:15

Dialysis

2.1K
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
2.1K
Dialysis01:27

Dialysis

2.2K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Dehydration Employing End-Tidal Carbon Dioxide in Children With Vomiting and Diarrhea.

Pediatric emergency care·2017
Same author

Periodontitis and early mortality among adults treated with hemodialysis: a multinational propensity-matched cohort study.

BMC nephrology·2017
Same author

Centre effects and peritoneal dialysis-related peritonitis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2017
Same author

Parental experiences and preferences as participants in pediatric research conducted in the emergency department.

CJEM·2017
Same author

Improving Nutrition Research in Nephrology: An Appetite for Change.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2017
Same author

Dietary interventions for adults with chronic kidney disease.

The Cochrane database of systematic reviews·2017

Related Experiment Video

Updated: May 1, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.0K

Biocompatible dialysis fluids for peritoneal dialysis.

Yeoungjee Cho1, David W Johnson, Jonathan C Craig

  • 1Department of Nephrology, Princess Alexandra Hospital, ARTS Building, Ipswich Rd, Woolloongabba, Queensland, Australia, 4012.

The Cochrane Database of Systematic Reviews
|March 28, 2014
PubMed
Summary

Biocompatible peritoneal dialysis (PD) solutions, including neutral pH low glucose degradation product (GDP) solutions and icodextrin, offer benefits for patients on PD. These solutions improve urine output, preserve renal function, and manage fluid overload without increasing adverse events or technique failure.

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.9K
A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
04:25

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

1.9K

Related Experiment Videos

Last Updated: May 1, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.0K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.9K
A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
04:25

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

1.9K

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Clinical Trials

Background:

  • Peritoneal dialysis (PD) longevity is challenged by technique failure, often linked to peritoneal membrane injury.
  • Development of 'biocompatible' PD solutions aims to mitigate peritoneal membrane damage.

Purpose of the Study:

  • To review the benefits and harms of biocompatible PD solutions compared to standard PD solutions.
  • Focus on neutral pH, low glucose degradation product (GDP) solutions and icodextrin.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched Cochrane Renal Group's Specialised Register, CENTRAL, MEDLINE, and EMBASE.
  • Included studies comparing biocompatible PD solutions (neutral pH, low GDP; icodextrin) with standard solutions; excluded amino acid-based solutions.

Main Results:

  • Neutral pH, low GDP solutions showed increased urine volume and improved residual renal function preservation with longer follow-up, with no impact on peritonitis or technique failure.
  • Icodextrin significantly reduced fluid overload and improved peritoneal ultrafiltration without compromising renal function or urine output.
  • No significant increase in adverse events was noted for either type of biocompatible solution.

Conclusions:

  • Neutral pH, low GDP PD solutions enhance urine output and preserve residual renal function beyond 12 months.
  • Icodextrin improves fluid management and ultrafiltration in PD patients.
  • Biocompatible PD solutions provide clinical benefits without increased risks, based on available evidence.